Johnson & Johnson's Gut Feeling About the Future of Medicine


In the following video, Fool contributor Maxx Chatsko discusses the recent investment by Johnson & Johnson into a tiny start-up called Second Genome. Although terms of the deal were not disclosed, it is not believed to have been very significant. In monetary terms, anyway. Second Genome is actively pursuing links between the bacteria living in your gut -- the microbiome -- and autoimmune diseases such as ulcerative colitis. There is growing evidence suggesting the microbiome plays a big role in our overall health, so Big Pharma would be well served to follow Johnson & Johnson's lead.

Is bigger really better?
Add the microbiome to the list. Involved in everything from baby powder to biotech, Johnson & Johnson's critics are convinced that the company is spread way too thin. If you want to know if J&J is nothing but a bloated corporate whale -- or a well-diversified giant that's perfect for your portfolio -- check out The Fool's new premium report outlining the Johnson & Johnson story in terms that any investor can understand. Claim your copy by clicking here now.

The article Johnson & Johnson's Gut Feeling About the Future of Medicine originally appeared on

Fool contributor Maxx Chatsko has no position in any stocks mentioned. Check out his personal portfolio, his CAPS page, or follow him on Twitter @BlacknGoldFool to keep up with his writing on energy, bioprocessing, and biotechnology.The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.